ID   AK1C2_HUMAN             Reviewed;         323 AA.
AC   P52895; A8K2N9; B4DKR9; Q14133; Q5SR16; Q7M4N1; Q96A71;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   10-MAY-2002, sequence version 3.
DT   28-JUN-2023, entry version 210.
DE   RecName: Full=Aldo-keto reductase family 1 member C2 {ECO:0000305};
DE            EC=1.-.-.- {ECO:0000269|PubMed:10998348, ECO:0000269|PubMed:14672942, ECO:0000269|PubMed:15929998, ECO:0000269|PubMed:17034817, ECO:0000269|PubMed:17442338, ECO:0000269|PubMed:19218247, ECO:0000269|PubMed:8573067};
DE            EC=1.1.1.112 {ECO:0000269|PubMed:8573067};
DE            EC=1.1.1.209 {ECO:0000269|PubMed:10998348};
DE            EC=1.1.1.53 {ECO:0000269|PubMed:10998348, ECO:0000269|PubMed:14672942};
DE            EC=1.1.1.62 {ECO:0000269|PubMed:10998348};
DE            EC=1.3.1.20 {ECO:0000269|PubMed:8573067};
DE   AltName: Full=3-alpha-HSD3;
DE   AltName: Full=Chlordecone reductase homolog HAKRD;
DE   AltName: Full=Dihydrodiol dehydrogenase 2 {ECO:0000303|PubMed:8573067};
DE            Short=DD-2 {ECO:0000303|PubMed:8573067};
DE            Short=DD2 {ECO:0000303|PubMed:8573067};
DE   AltName: Full=Dihydrodiol dehydrogenase/bile acid-binding protein;
DE            Short=DD/BABP;
DE   AltName: Full=Type III 3-alpha-hydroxysteroid dehydrogenase;
DE            EC=1.1.1.357 {ECO:0000269|PubMed:15929998, ECO:0000269|PubMed:17034817, ECO:0000269|PubMed:17442338, ECO:0000269|PubMed:8573067};
GN   Name=AKR1C2; Synonyms=DDH2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Liver;
RX   PubMed=8274401; DOI=10.1016/0960-0760(93)90308-j;
RA   Qin K.-N., New M.I., Cheng K.-C.;
RT   "Molecular cloning of multiple cDNAs encoding human enzymes structurally
RT   related to 3 alpha-hydroxysteroid dehydrogenase.";
RL   J. Steroid Biochem. Mol. Biol. 46:673-679(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Colon;
RX   PubMed=8011662; DOI=10.1016/0005-2728(94)90144-9;
RA   Ciaccio P.J., Tew K.D.;
RT   "cDNA and deduced amino acid sequences of a human colon dihydrodiol
RT   dehydrogenase.";
RL   Biochim. Biophys. Acta 1186:129-132(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1), AND VARIANT TYR-46.
RX   PubMed=7959017; DOI=10.1016/0378-1119(94)90176-7;
RA   Qin K.-N., Khanna M., Cheng K.-C.;
RT   "Structure of a gene coding for human dihydrodiol dehydrogenase/bile acid-
RT   binding protein.";
RL   Gene 149:357-361(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1).
RC   TISSUE=Prostate;
RX   PubMed=8920937; DOI=10.1006/bbrc.1996.1684;
RA   Dufort I., Soucy P., Labrie F., Luu-The V.;
RT   "Molecular cloning of human type 3 3 alpha-hydroxysteroid dehydrogenase
RT   that differs from 20 alpha-hydroxysteroid dehydrogenase by seven amino
RT   acids.";
RL   Biochem. Biophys. Res. Commun. 228:474-479(1996).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Liver;
RX   PubMed=9716498; DOI=10.1042/bj3340399;
RA   Shiraishi H., Ishikura S., Matsuura K., Deyashiki Y., Ninomiya M.,
RA   Sakai S., Hara A.;
RT   "Sequence of the cDNA of a human dihydrodiol dehydrogenase isoform (AKR1C2)
RT   and tissue distribution of its mRNA.";
RL   Biochem. J. 334:399-405(1998).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1).
RC   TISSUE=Liver;
RX   PubMed=10672042; DOI=10.1046/j.1365-2443.2000.00310.x;
RA   Nishizawa M., Nakajima T., Yasuda K., Kanzaki H., Sasaguri Y., Watanabe K.,
RA   Ito S.;
RT   "Close kinship of human 20alpha-hydroxysteroid dehydrogenase gene with
RT   three aldo-keto reductase genes.";
RL   Genes Cells 5:111-125(2000).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Tongue;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Cahill P., Camire D., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S., Corby N.,
RA   Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L., Frankish A.,
RA   Frankland J.A., Garner P., Garnett J., Gribble S., Griffiths C.,
RA   Grocock R., Gustafson E., Hammond S., Harley J.L., Hart E., Heath P.D.,
RA   Ho T.P., Hopkins B., Horne J., Howden P.J., Huckle E., Hynds C.,
RA   Johnson C., Johnson D., Kana A., Kay M., Kimberley A.M., Kershaw J.K.,
RA   Kokkinaki M., Laird G.K., Lawlor S., Lee H.M., Leongamornlert D.A.,
RA   Laird G., Lloyd C., Lloyd D.M., Loveland J., Lovell J., McLaren S.,
RA   McLay K.E., McMurray A., Mashreghi-Mohammadi M., Matthews L., Milne S.,
RA   Nickerson T., Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V.,
RA   Peck A.I., Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A.,
RA   Ross M.T., Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W., Tracey A.,
RA   Tromans A., Tsolas J., Wall M., Walsh J., Wang H., Weinstock K., West A.P.,
RA   Willey D.L., Whitehead S.L., Wilming L., Wray P.W., Young L., Chen Y.,
RA   Lovering R.C., Moschonas N.K., Siebert R., Fechtel K., Bentley D.,
RA   Durbin R.M., Hubbard T., Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lung, and Urinary bladder;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   PROTEIN SEQUENCE OF 2-31; 40-62; 69-100; 105-131; 137-153; 162-206;
RP   209-231; 250-269 AND 271-323, FUNCTION, CATALYTIC ACTIVITY, ACTIVITY
RP   REGULATION, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=8573067; DOI=10.1042/bj3130373;
RA   Hara A., Matsuura K., Tamada Y., Sato K., Miyabe Y., Deyashiki Y.,
RA   Ishida N.;
RT   "Relationship of human liver dihydrodiol dehydrogenases to hepatic bile-
RT   acid-binding protein and an oxidoreductase of human colon cells.";
RL   Biochem. J. 313:373-376(1996).
RN   [12]
RP   PROTEIN SEQUENCE OF 10-29; 40-55; 76-101; 105-128; 137-146; 162-197;
RP   208-223; 259-270 AND 305-322, AND SUBCELLULAR LOCATION.
RC   TISSUE=Liver;
RX   PubMed=8486699; DOI=10.1016/s0021-9258(18)82220-7;
RA   Stolz A., Hammond L., Lou H., Takikawa H., Ronk M., Shively J.E.;
RT   "cDNA cloning and expression of the human hepatic bile acid-binding
RT   protein. A member of the monomeric reductase gene family.";
RL   J. Biol. Chem. 268:10448-10457(1993).
RN   [13]
RP   FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, AND SUBSTRATE
RP   SPECIFICITY.
RX   PubMed=10998348; DOI=10.1042/0264-6021:3510067;
RA   Penning T.M., Burczynski M.E., Jez J.M., Hung C.F., Lin H.K., Ma H.,
RA   Moore M., Palackal N., Ratnam K.;
RT   "Human 3alpha-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the
RT   aldo-keto reductase superfamily: functional plasticity and tissue
RT   distribution reveals roles in the inactivation and formation of male and
RT   female sex hormones.";
RL   Biochem. J. 351:67-77(2000).
RN   [14]
RP   FUNCTION, CATALYTIC ACTIVITY, PATHWAY, AND ACTIVITY REGULATION.
RX   PubMed=14672942; DOI=10.1074/jbc.m313308200;
RA   Steckelbroeck S., Jin Y., Gopishetty S., Oyesanmi B., Penning T.M.;
RT   "Human cytosolic 3alpha-hydroxysteroid dehydrogenases of the aldo-keto
RT   reductase superfamily display significant 3beta-hydroxysteroid
RT   dehydrogenase activity: implications for steroid hormone metabolism and
RT   action.";
RL   J. Biol. Chem. 279:10784-10795(2004).
RN   [15]
RP   FUNCTION, CATALYTIC ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=19218247; DOI=10.1074/jbc.m809465200;
RA   Jin Y., Duan L., Lee S.H., Kloosterboer H.J., Blair I.A., Penning T.M.;
RT   "Human cytosolic hydroxysteroid dehydrogenases of the aldo-ketoreductase
RT   superfamily catalyze reduction of conjugated steroids: implications for
RT   phase I and phase II steroid hormone metabolism.";
RL   J. Biol. Chem. 284:10013-10022(2009).
RN   [16]
RP   TISSUE SPECIFICITY, VARIANTS SRXY8 VAL-79; GLN-90; GLN-222 AND THR-300, AND
RP   CHARACTERIZATION OF VARIANTS SRXY8 VAL-79; GLN-90; GLN-222 AND THR-300.
RX   PubMed=21802064; DOI=10.1016/j.ajhg.2011.06.009;
RA   Fluck C.E., Meyer-Boni M., Pandey A.V., Kempna P., Miller W.L.,
RA   Schoenle E.J., Biason-Lauber A.;
RT   "Why boys will be boys: two pathways of fetal testicular androgen
RT   biosynthesis are needed for male sexual differentiation.";
RL   Am. J. Hum. Genet. 89:201-218(2011).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) IN COMPLEX WITH NADP AND
RP   URSODEOXYCHOLATE.
RX   PubMed=11513593; DOI=10.1021/bi010919a;
RA   Jin Y., Stayrook S.E., Albert R.H., Palackal N.T., Penning T.M., Lewis M.;
RT   "Crystal structure of human type III 3alpha-hydroxysteroid
RT   dehydrogenase/bile acid binding protein complexed with NADP(+) and
RT   ursodeoxycholate.";
RL   Biochemistry 40:10161-10168(2001).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (1.25 ANGSTROMS) IN COMPLEX WITH NADP AND
RP   TESTOSTERONE.
RX   PubMed=11514561; DOI=10.1074/jbc.m105610200;
RA   Nahoum V., Gangloff A., Legrand P., Zhu D.-W., Cantin L., Zhorov B.S.,
RA   Luu-The V., Labrie F., Breton R., Lin S.X.;
RT   "Structure of the human 3alpha-hydroxysteroid dehydrogenase type 3 in
RT   complex with testosterone and NADP at 1.25-A resolution.";
RL   J. Biol. Chem. 276:42091-42098(2001).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) OF 2-323 IN COMPLEX WITH NADP,
RP   FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF ARG-301 AND ARG-304.
RX   PubMed=15929998; DOI=10.1110/ps.051353205;
RA   Couture J.F., de Jesus-Tran K.P., Roy A.M., Cantin L., Cote P.L.,
RA   Legrand P., Luu-The V., Labrie F., Breton R.;
RT   "Comparison of crystal structures of human type 3 3alpha-hydroxysteroid
RT   dehydrogenase reveals an 'induced-fit' mechanism and a conserved basic
RT   motif involved in the binding of androgen.";
RL   Protein Sci. 14:1485-1497(2005).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) IN COMPLEX WITH NADP, FUNCTION, AND
RP   CATALYTIC ACTIVITY.
RX   PubMed=17034817; DOI=10.1016/j.jmb.2006.09.030;
RA   Faucher F., Pereira de Jesus-Tran K., Cantin L., Luu-The V., Labrie F.,
RA   Breton R.;
RT   "Crystal structures of mouse 17alpha-hydroxysteroid dehydrogenase
RT   (apoenzyme and enzyme-NADP(H) binary complex): identification of molecular
RT   determinants responsible for the unique 17alpha-reductive activity of this
RT   enzyme.";
RL   J. Mol. Biol. 364:747-763(2006).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) OF 3-323 IN COMPLEX WITH NADP AND
RP   HYDROXYANDROSTERONE, FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF
RP   TYR-24 AND LYS-31.
RX   PubMed=17442338; DOI=10.1016/j.jmb.2007.03.058;
RA   Faucher F., Cantin L., Pereira de Jesus-Tran K., Lemieux M., Luu-The V.,
RA   Labrie F., Breton R.;
RT   "Mouse 17alpha-hydroxysteroid dehydrogenase (AKR1C21) binds steroids
RT   differently from other aldo-keto reductases: identification and
RT   characterization of amino acid residues critical for substrate binding.";
RL   J. Mol. Biol. 369:525-540(2007).
CC   -!- FUNCTION: Cytosolic aldo-keto reductase that catalyzes the NADH and
CC       NADPH-dependent reduction of ketosteroids to hydroxysteroids
CC       (PubMed:19218247). Most probably acts as a reductase in vivo since the
CC       oxidase activity measured in vitro is inhibited by physiological
CC       concentrations of NADPH (PubMed:14672942). Displays a broad positional
CC       specificity acting on positions 3, 17 and 20 of steroids and regulates
CC       the metabolism of hormones like estrogens and androgens
CC       (PubMed:10998348). Works in concert with the 5-alpha/5-beta-steroid
CC       reductases to convert steroid hormones into the 3-alpha/5-alpha and 3-
CC       alpha/5-beta-tetrahydrosteroids. Catalyzes the inactivation of the most
CC       potent androgen 5-alpha-dihydrotestosterone (5-alpha-DHT) to 5-alpha-
CC       androstane-3-alpha,17-beta-diol (3-alpha-diol) (PubMed:15929998,
CC       PubMed:17034817, PubMed:17442338, PubMed:8573067). Also specifically
CC       able to produce 17beta-hydroxy-5alpha-androstan-3-one/5alphaDHT
CC       (PubMed:10998348). May also reduce conjugated steroids such as 5alpha-
CC       dihydrotestosterone sulfate (PubMed:19218247). Displays affinity for
CC       bile acids (PubMed:8486699). {ECO:0000269|PubMed:10998348,
CC       ECO:0000269|PubMed:14672942, ECO:0000269|PubMed:15929998,
CC       ECO:0000269|PubMed:17034817, ECO:0000269|PubMed:17442338,
CC       ECO:0000269|PubMed:19218247, ECO:0000269|PubMed:8486699,
CC       ECO:0000269|PubMed:8573067}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 3alpha-hydroxysteroid + NADP(+) = a 3-oxosteroid + H(+) +
CC         NADPH; Xref=Rhea:RHEA:34783, ChEBI:CHEBI:15378, ChEBI:CHEBI:36835,
CC         ChEBI:CHEBI:47788, ChEBI:CHEBI:57783, ChEBI:CHEBI:58349;
CC         EC=1.1.1.357; Evidence={ECO:0000269|PubMed:15929998,
CC         ECO:0000269|PubMed:17034817, ECO:0000269|PubMed:17442338,
CC         ECO:0000269|PubMed:8573067};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 3alpha-hydroxysteroid + NAD(+) = a 3-oxosteroid + H(+) +
CC         NADH; Xref=Rhea:RHEA:34779, ChEBI:CHEBI:15378, ChEBI:CHEBI:36835,
CC         ChEBI:CHEBI:47788, ChEBI:CHEBI:57540, ChEBI:CHEBI:57945;
CC         EC=1.1.1.357; Evidence={ECO:0000269|PubMed:15929998,
CC         ECO:0000269|PubMed:17034817, ECO:0000269|PubMed:17442338,
CC         ECO:0000269|PubMed:8573067};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=5alpha-androstane-3alpha,17beta-diol + NADP(+) = 17beta-
CC         hydroxy-5alpha-androstan-3-one + H(+) + NADPH; Xref=Rhea:RHEA:42116,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:16330, ChEBI:CHEBI:36713,
CC         ChEBI:CHEBI:57783, ChEBI:CHEBI:58349;
CC         Evidence={ECO:0000269|PubMed:10998348, ECO:0000269|PubMed:14672942,
CC         ECO:0000269|PubMed:19218247};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:42117;
CC         Evidence={ECO:0000269|PubMed:10998348};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:42118;
CC         Evidence={ECO:0000269|PubMed:10998348, ECO:0000269|PubMed:14672942,
CC         ECO:0000269|PubMed:19218247};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=5alpha-androstane-3alpha,17beta-diol + NAD(+) = 17beta-
CC         hydroxy-5alpha-androstan-3-one + H(+) + NADH; Xref=Rhea:RHEA:42004,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:16330, ChEBI:CHEBI:36713,
CC         ChEBI:CHEBI:57540, ChEBI:CHEBI:57945; EC=1.1.1.53;
CC         Evidence={ECO:0000269|PubMed:10998348, ECO:0000269|PubMed:14672942};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:42005;
CC         Evidence={ECO:0000269|PubMed:10998348, ECO:0000269|PubMed:14672942};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:42006;
CC         Evidence={ECO:0000269|PubMed:10998348};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=5alpha-androstane-3alpha,17beta-diol + NAD(+) = androsterone +
CC         H(+) + NADH; Xref=Rhea:RHEA:42124, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:16032, ChEBI:CHEBI:36713, ChEBI:CHEBI:57540,
CC         ChEBI:CHEBI:57945; Evidence={ECO:0000269|PubMed:14672942};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:42125;
CC         Evidence={ECO:0000269|PubMed:14672942};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=17beta-estradiol + NADP(+) = estrone + H(+) + NADPH;
CC         Xref=Rhea:RHEA:24616, ChEBI:CHEBI:15378, ChEBI:CHEBI:16469,
CC         ChEBI:CHEBI:17263, ChEBI:CHEBI:57783, ChEBI:CHEBI:58349; EC=1.1.1.62;
CC         Evidence={ECO:0000269|PubMed:10998348};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:24617;
CC         Evidence={ECO:0000269|PubMed:10998348};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:24618;
CC         Evidence={ECO:0000269|PubMed:10998348};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=17beta-estradiol + NAD(+) = estrone + H(+) + NADH;
CC         Xref=Rhea:RHEA:24612, ChEBI:CHEBI:15378, ChEBI:CHEBI:16469,
CC         ChEBI:CHEBI:17263, ChEBI:CHEBI:57540, ChEBI:CHEBI:57945; EC=1.1.1.62;
CC         Evidence={ECO:0000269|PubMed:10998348};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:24613;
CC         Evidence={ECO:0000269|PubMed:10998348};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:24614;
CC         Evidence={ECO:0000269|PubMed:10998348};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(20S)-hydroxypregn-4-en-3-one + NADP(+) = H(+) + NADPH +
CC         progesterone; Xref=Rhea:RHEA:42112, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:17026, ChEBI:CHEBI:28453, ChEBI:CHEBI:57783,
CC         ChEBI:CHEBI:58349; Evidence={ECO:0000269|PubMed:10998348};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:42113;
CC         Evidence={ECO:0000269|PubMed:10998348};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:42114;
CC         Evidence={ECO:0000269|PubMed:10998348};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(20S)-hydroxypregn-4-en-3-one + NAD(+) = H(+) + NADH +
CC         progesterone; Xref=Rhea:RHEA:42108, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:17026, ChEBI:CHEBI:28453, ChEBI:CHEBI:57540,
CC         ChEBI:CHEBI:57945; Evidence={ECO:0000269|PubMed:10998348};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:42109;
CC         Evidence={ECO:0000269|PubMed:10998348};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:42110;
CC         Evidence={ECO:0000269|PubMed:10998348};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=androsterone + NADP(+) = 5alpha-androstan-3,17-dione + H(+) +
CC         NADPH; Xref=Rhea:RHEA:20377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15994,
CC         ChEBI:CHEBI:16032, ChEBI:CHEBI:57783, ChEBI:CHEBI:58349;
CC         EC=1.1.1.209; Evidence={ECO:0000269|PubMed:10998348};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:20378;
CC         Evidence={ECO:0000269|PubMed:10998348};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(3beta,5alpha,17beta)-3-hydroxy-androstan-17-yl sulfate +
CC         NADP(+) = 5alpha-dihydrotestosterone sulfate + H(+) + NADPH;
CC         Xref=Rhea:RHEA:53136, ChEBI:CHEBI:15378, ChEBI:CHEBI:57783,
CC         ChEBI:CHEBI:58349, ChEBI:CHEBI:133105, ChEBI:CHEBI:136982;
CC         Evidence={ECO:0000269|PubMed:19218247};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:53138;
CC         Evidence={ECO:0000269|PubMed:19218247};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(1R,2R)-1,2-dihydrobenzene-1,2-diol + NADP(+) = catechol +
CC         H(+) + NADPH; Xref=Rhea:RHEA:16729, ChEBI:CHEBI:10702,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:18135, ChEBI:CHEBI:57783,
CC         ChEBI:CHEBI:58349; EC=1.3.1.20;
CC         Evidence={ECO:0000269|PubMed:8573067};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(S)-indan-1-ol + NAD(+) = H(+) + indan-1-one + NADH;
CC         Xref=Rhea:RHEA:16317, ChEBI:CHEBI:15378, ChEBI:CHEBI:17404,
CC         ChEBI:CHEBI:57540, ChEBI:CHEBI:57945, ChEBI:CHEBI:156384;
CC         EC=1.1.1.112; Evidence={ECO:0000269|PubMed:8573067};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(S)-indan-1-ol + NADP(+) = H(+) + indan-1-one + NADPH;
CC         Xref=Rhea:RHEA:16321, ChEBI:CHEBI:15378, ChEBI:CHEBI:17404,
CC         ChEBI:CHEBI:57783, ChEBI:CHEBI:58349, ChEBI:CHEBI:156384;
CC         EC=1.1.1.112; Evidence={ECO:0000269|PubMed:8573067};
CC   -!- ACTIVITY REGULATION: Inhibited by hexestrol with an IC(50) of 2.8 uM,
CC       1,10-phenanthroline with an IC(50) of 2100 uM, 1,7-phenanthroline with
CC       an IC(50) of 1500 uM, flufenamic acid with an IC(50) of 0.9 uM,
CC       indomethacin with an IC(50) of 75 uM, ibuprofen with an IC(50) of 6.9
CC       uM, lithocholic acid with an IC(50) of 0.07 uM, ursodeoxycholic acid
CC       with an IC(50) of 0.08 uM and chenodeoxycholic acid with an IC(50) of
CC       0.13 uM (PubMed:8573067). The oxidation reaction is inhibited by low
CC       micromolar concentrations of NADPH (PubMed:14672942).
CC       {ECO:0000269|PubMed:14672942, ECO:0000269|PubMed:8573067}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=260 uM for (s)-tetralol {ECO:0000269|PubMed:8573067};
CC         KM=520 uM for (s)-indan-1-ol {ECO:0000269|PubMed:8573067};
CC         KM=5000 uM for benzene dihydrodiol {ECO:0000269|PubMed:8573067};
CC         KM=1 uM for 5-beta-pregnane-3-alpha,20-alpha-diol
CC         {ECO:0000269|PubMed:8573067};
CC         KM=208 uM for 9-alpha,11-beta-prostaglandin F(2)
CC         {ECO:0000269|PubMed:8573067};
CC         KM=0.3 uM for 5-beta-androstane-3,17-dione
CC         {ECO:0000269|PubMed:8573067};
CC         KM=79 uM for prostaglandin D2 {ECO:0000269|PubMed:8573067};
CC         KM=26 uM for 17beta-hydroxy-5alpha-androstan-3-one (in the reduction
CC         assay) {ECO:0000269|PubMed:10998348};
CC         KM=2.9 uM for 17beta-hydroxy-5alpha-androstan-3-one (in the reduction
CC         assay) {ECO:0000269|PubMed:19218247};
CC         KM=6.26 uM for 5alpha-androstan-3,17-dione (in the reduction assay)
CC         {ECO:0000269|PubMed:10998348};
CC         KM=9.73 uM for 3alpha-hydroxy-5alpha-androstan-17-one/androsterone
CC         (in the oxidation assay) {ECO:0000269|PubMed:10998348};
CC         KM=22 uM for 5alpha-androstane-3alpha,17beta-diol (in the oxidation
CC         assay) {ECO:0000269|PubMed:10998348};
CC         KM=4.2 uM for 5alpha-dihydrotestosterone sulfate (in the reduction
CC         assay) {ECO:0000269|PubMed:19218247};
CC         Vmax=6.24 nmol/min/mg enzyme for the reduction of
CC         17beta-hydroxy-5alpha-androstan-3-one {ECO:0000269|PubMed:10998348};
CC         Vmax=37.8 nmol/min/mg enzyme for the reduction of
CC         5alpha-androstan-3,17-dione {ECO:0000269|PubMed:10998348};
CC         Vmax=11.3 nmol/min/mg enzyme for the oxidation of
CC         3alpha-hydroxy-5alpha-androstan-17-one/androsterone
CC         {ECO:0000269|PubMed:10998348};
CC         Vmax=6.58 nmol/min/mg enzyme for the oxidation of
CC         5alpha-androstane-3alpha,17beta-diol {ECO:0000269|PubMed:10998348};
CC         Note=kcat is 0.66 min-1 for the reduction of
CC         17beta-hydroxy-5alpha-androstan-3-one (PubMed:10998348). kcat is 1.98
CC         min-1 for the reduction of 17beta-hydroxy-5alpha-androstan-3-one
CC         (PubMed:19218247). kcat is 1.39 min-1 for the reduction of
CC         5alpha-androstan-3,17-dione (PubMed:10998348). kcat is 0.42 min-1 for
CC         the oxidation of 3alpha-hydroxy-5alpha-androstan-17-one/androsterone
CC         (PubMed:10998348). kcat is 0.24 min-1 for the oxidation of
CC         5alpha-androstane-3alpha,17beta-diol (PubMed:10998348). kcat is 1.0
CC         min-1 for the reduction of 5alpha-dihydrotestosterone sulfate
CC         (PubMed:19218247). {ECO:0000269|PubMed:10998348,
CC         ECO:0000269|PubMed:19218247};
CC   -!- PATHWAY: Steroid metabolism. {ECO:0000269|PubMed:14672942}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol {ECO:0000305|PubMed:8486699}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P52895-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P52895-2; Sequence=VSP_043779, VSP_043780;
CC   -!- TISSUE SPECIFICITY: Expressed in fetal testes. Expressed in fetal and
CC       adult adrenal glands. {ECO:0000269|PubMed:21802064}.
CC   -!- DISEASE: 46,XY sex reversal 8 (SRXY8) [MIM:614279]: A disorder of sex
CC       development. Affected individuals have a 46,XY karyotype but present as
CC       phenotypically normal females. {ECO:0000269|PubMed:21802064}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the aldo/keto reductase family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; S68330; AAD14013.1; -; mRNA.
DR   EMBL; U05598; AAA20937.1; -; mRNA.
DR   EMBL; L32592; AAB38486.1; -; Genomic_DNA.
DR   EMBL; AB021654; BAA36169.1; -; mRNA.
DR   EMBL; AB031084; BAA92884.1; -; mRNA.
DR   EMBL; AB032153; BAA92891.1; -; Genomic_DNA.
DR   EMBL; AK290304; BAF82993.1; -; mRNA.
DR   EMBL; AK296686; BAG59281.1; -; mRNA.
DR   EMBL; BT006653; AAP35299.1; -; mRNA.
DR   EMBL; AL391427; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL713867; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC007024; AAH07024.1; -; mRNA.
DR   EMBL; BC063574; AAH63574.1; -; mRNA.
DR   CCDS; CCDS44350.1; -. [P52895-2]
DR   CCDS; CCDS7062.1; -. [P52895-1]
DR   PIR; I73676; I73676.
DR   PIR; JC5240; JC5240.
DR   PIR; S61516; S61516.
DR   RefSeq; NP_001128713.1; NM_001135241.2. [P52895-2]
DR   RefSeq; NP_001345.1; NM_001354.5. [P52895-1]
DR   RefSeq; NP_995317.1; NM_205845.2. [P52895-1]
DR   PDB; 1IHI; X-ray; 3.00 A; A/B=1-323.
DR   PDB; 1J96; X-ray; 1.25 A; A/B=2-323.
DR   PDB; 1XJB; X-ray; 1.90 A; A/B=2-323.
DR   PDB; 2HDJ; X-ray; 2.00 A; A/B=1-323.
DR   PDB; 2IPJ; X-ray; 1.80 A; A/B=3-323.
DR   PDB; 4JQ1; X-ray; 1.60 A; A/B=1-323.
DR   PDB; 4JQ2; X-ray; 1.75 A; A/B=1-323.
DR   PDB; 4JQ3; X-ray; 1.75 A; A/B=1-323.
DR   PDB; 4JQ4; X-ray; 1.52 A; A/B=1-323.
DR   PDB; 4JQA; X-ray; 1.45 A; A/B=1-323.
DR   PDB; 4JTQ; X-ray; 1.60 A; A/B=1-323.
DR   PDB; 4JTR; X-ray; 1.30 A; A/B=1-323.
DR   PDB; 4L1W; X-ray; 2.20 A; A/B=2-323.
DR   PDB; 4L1X; X-ray; 2.00 A; A/B=2-323.
DR   PDB; 4XO6; X-ray; 1.20 A; A/B=2-323.
DR   PDB; 4XO7; X-ray; 1.75 A; A/B=1-323.
DR   PDBsum; 1IHI; -.
DR   PDBsum; 1J96; -.
DR   PDBsum; 1XJB; -.
DR   PDBsum; 2HDJ; -.
DR   PDBsum; 2IPJ; -.
DR   PDBsum; 4JQ1; -.
DR   PDBsum; 4JQ2; -.
DR   PDBsum; 4JQ3; -.
DR   PDBsum; 4JQ4; -.
DR   PDBsum; 4JQA; -.
DR   PDBsum; 4JTQ; -.
DR   PDBsum; 4JTR; -.
DR   PDBsum; 4L1W; -.
DR   PDBsum; 4L1X; -.
DR   PDBsum; 4XO6; -.
DR   PDBsum; 4XO7; -.
DR   AlphaFoldDB; P52895; -.
DR   SMR; P52895; -.
DR   BioGRID; 108013; 58.
DR   IntAct; P52895; 6.
DR   STRING; 9606.ENSP00000370129; -.
DR   BindingDB; P52895; -.
DR   ChEMBL; CHEMBL5847; -.
DR   DrugBank; DB06777; Chenodeoxycholic acid.
DR   DrugBank; DB07768; Epitestosterone.
DR   DrugBank; DB01039; Fenofibrate.
DR   DrugBank; DB13751; Glycyrrhizic acid.
DR   DrugBank; DB06077; Lumateperone.
DR   DrugBank; DB00959; Methylprednisolone.
DR   DrugBank; DB00461; Nabumetone.
DR   DrugBank; DB00157; NADH.
DR   DrugBank; DB03461; Nicotinamide adenine dinucleotide phosphate.
DR   DrugBank; DB00776; Oxcarbazepine.
DR   DrugBank; DB12612; Ozanimod.
DR   DrugBank; DB01586; Ursodeoxycholic acid.
DR   DrugCentral; P52895; -.
DR   SwissLipids; SLP:000000803; -.
DR   iPTMnet; P52895; -.
DR   PhosphoSitePlus; P52895; -.
DR   SwissPalm; P52895; -.
DR   BioMuta; AKR1C2; -.
DR   DMDM; 20532374; -.
DR   EPD; P52895; -.
DR   jPOST; P52895; -.
DR   MassIVE; P52895; -.
DR   MaxQB; P52895; -.
DR   PaxDb; P52895; -.
DR   PeptideAtlas; P52895; -.
DR   ProteomicsDB; 56548; -. [P52895-1]
DR   ProteomicsDB; 56549; -. [P52895-2]
DR   Antibodypedia; 23996; 316 antibodies from 33 providers.
DR   CPTC; P52895; 3 antibodies.
DR   DNASU; 1646; -.
DR   Ensembl; ENST00000380753.9; ENSP00000370129.4; ENSG00000151632.18. [P52895-1]
DR   Ensembl; ENST00000455190.2; ENSP00000408440.1; ENSG00000151632.18. [P52895-2]
DR   GeneID; 1646; -.
DR   KEGG; hsa:1646; -.
DR   MANE-Select; ENST00000380753.9; ENSP00000370129.4; NM_001393392.1; NP_001380321.1.
DR   UCSC; uc010qao.2; human. [P52895-1]
DR   AGR; HGNC:385; -.
DR   CTD; 1646; -.
DR   DisGeNET; 1646; -.
DR   GeneCards; AKR1C2; -.
DR   HGNC; HGNC:385; AKR1C2.
DR   HPA; ENSG00000151632; Tissue enhanced (adipose tissue, liver).
DR   MalaCards; AKR1C2; -.
DR   MIM; 600450; gene.
DR   MIM; 614279; phenotype.
DR   neXtProt; NX_P52895; -.
DR   OpenTargets; ENSG00000151632; -.
DR   Orphanet; 443087; 46,XY disorder of sex development due to testicular 17,20-desmolase deficiency.
DR   PharmGKB; PA24678; -.
DR   VEuPathDB; HostDB:ENSG00000151632; -.
DR   eggNOG; KOG1577; Eukaryota.
DR   GeneTree; ENSGT00940000167640; -.
DR   HOGENOM; CLU_023205_19_2_1; -.
DR   InParanoid; P52895; -.
DR   OMA; KLWGTEQ; -.
DR   OrthoDB; 890110at2759; -.
DR   PhylomeDB; P52895; -.
DR   TreeFam; TF106492; -.
DR   BioCyc; MetaCyc:HS07754-MON; -.
DR   BRENDA; 1.1.1.213; 2681.
DR   BRENDA; 1.1.1.357; 2681.
DR   BRENDA; 1.1.1.50; 2681.
DR   BRENDA; 1.3.1.20; 2681.
DR   PathwayCommons; P52895; -.
DR   Reactome; R-HSA-193368; Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol.
DR   Reactome; R-HSA-193775; Synthesis of bile acids and bile salts via 24-hydroxycholesterol.
DR   Reactome; R-HSA-193807; Synthesis of bile acids and bile salts via 27-hydroxycholesterol.
DR   SABIO-RK; P52895; -.
DR   SignaLink; P52895; -.
DR   SIGNOR; P52895; -.
DR   BioGRID-ORCS; 1646; 19 hits in 1091 CRISPR screens.
DR   ChiTaRS; AKR1C2; human.
DR   EvolutionaryTrace; P52895; -.
DR   GenomeRNAi; 1646; -.
DR   Pharos; P52895; Tchem.
DR   PRO; PR:P52895; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   RNAct; P52895; protein.
DR   Bgee; ENSG00000151632; Expressed in islet of Langerhans and 92 other tissues.
DR   ExpressionAtlas; P52895; baseline and differential.
DR   Genevisible; P52895; HS.
DR   GO; GO:0005829; C:cytosol; IBA:GO_Central.
DR   GO; GO:0044594; F:17-beta-hydroxysteroid dehydrogenase (NAD+) activity; IEA:RHEA.
DR   GO; GO:0004032; F:alditol:NADP+ 1-oxidoreductase activity; IDA:UniProtKB.
DR   GO; GO:0047044; F:androstan-3-alpha,17-beta-diol dehydrogenase activity; IEA:UniProtKB-EC.
DR   GO; GO:0047023; F:androsterone dehydrogenase activity; IBA:GO_Central.
DR   GO; GO:0032052; F:bile acid binding; IDA:UniProtKB.
DR   GO; GO:0031406; F:carboxylic acid binding; IDA:UniProtKB.
DR   GO; GO:0004303; F:estradiol 17-beta-dehydrogenase [NAD(P)] activity; IEA:UniProtKB-EC.
DR   GO; GO:0047718; F:indanol dehydrogenase activity; IEA:UniProtKB-EC.
DR   GO; GO:0047086; F:ketosteroid monooxygenase activity; IDA:UniProtKB.
DR   GO; GO:0016655; F:oxidoreductase activity, acting on NAD(P)H, quinone or similar compound as acceptor; IDA:UniProtKB.
DR   GO; GO:0018636; F:phenanthrene 9,10-monooxygenase activity; IDA:UniProtKB.
DR   GO; GO:0047115; F:trans-1,2-dihydrobenzene-1,2-diol dehydrogenase activity; IDA:UniProtKB.
DR   GO; GO:0071395; P:cellular response to jasmonic acid stimulus; IDA:UniProtKB.
DR   GO; GO:0071799; P:cellular response to prostaglandin D stimulus; IDA:UniProtKB.
DR   GO; GO:0044597; P:daunorubicin metabolic process; IMP:UniProtKB.
DR   GO; GO:0007586; P:digestion; IDA:UniProtKB.
DR   GO; GO:0044598; P:doxorubicin metabolic process; IMP:UniProtKB.
DR   GO; GO:0030855; P:epithelial cell differentiation; IEP:UniProtKB.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IDA:UniProtKB.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; IDA:UniProtKB.
DR   GO; GO:0042448; P:progesterone metabolic process; IDA:UniProtKB.
DR   GO; GO:0006693; P:prostaglandin metabolic process; IDA:UniProtKB.
DR   GO; GO:0008202; P:steroid metabolic process; IDA:UniProtKB.
DR   CDD; cd19108; AKR_AKR1C1-35; 1.
DR   Gene3D; 3.20.20.100; NADP-dependent oxidoreductase domain; 1.
DR   InterPro; IPR020471; AKR.
DR   InterPro; IPR044482; AKR1C.
DR   InterPro; IPR018170; Aldo/ket_reductase_CS.
DR   InterPro; IPR023210; NADP_OxRdtase_dom.
DR   InterPro; IPR036812; NADP_OxRdtase_dom_sf.
DR   PANTHER; PTHR11732:SF153; ALDO-KETO REDUCTASE FAMILY 1 MEMBER C1-RELATED; 1.
DR   PANTHER; PTHR11732; ALDO/KETO REDUCTASE; 1.
DR   Pfam; PF00248; Aldo_ket_red; 1.
DR   PIRSF; PIRSF000097; AKR; 1.
DR   PRINTS; PR00069; ALDKETRDTASE.
DR   SUPFAM; SSF51430; NAD(P)-linked oxidoreductase; 1.
DR   PROSITE; PS00062; ALDOKETO_REDUCTASE_2; 1.
DR   PROSITE; PS00063; ALDOKETO_REDUCTASE_3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cytoplasm; Direct protein sequencing;
KW   Disease variant; Lipid metabolism; NADP; Oxidoreductase;
KW   Reference proteome; Steroid metabolism.
FT   CHAIN           1..323
FT                   /note="Aldo-keto reductase family 1 member C2"
FT                   /id="PRO_0000124637"
FT   ACT_SITE        55
FT                   /note="Proton donor"
FT   BINDING         20..24
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000269|PubMed:11513593,
FT                   ECO:0000269|PubMed:11514561, ECO:0000269|PubMed:15929998,
FT                   ECO:0000269|PubMed:17034817, ECO:0000269|PubMed:17442338"
FT   BINDING         24
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250"
FT   BINDING         50
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000269|PubMed:11513593,
FT                   ECO:0000269|PubMed:11514561, ECO:0000269|PubMed:15929998,
FT                   ECO:0000269|PubMed:17034817, ECO:0000269|PubMed:17442338"
FT   BINDING         117
FT                   /ligand="substrate"
FT   BINDING         166..167
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000269|PubMed:11513593,
FT                   ECO:0000269|PubMed:11514561, ECO:0000269|PubMed:15929998,
FT                   ECO:0000269|PubMed:17034817, ECO:0000269|PubMed:17442338"
FT   BINDING         190
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000269|PubMed:11513593,
FT                   ECO:0000269|PubMed:11514561, ECO:0000269|PubMed:15929998,
FT                   ECO:0000269|PubMed:17034817, ECO:0000269|PubMed:17442338"
FT   BINDING         216..222
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000269|PubMed:11513593,
FT                   ECO:0000269|PubMed:11514561, ECO:0000269|PubMed:15929998,
FT                   ECO:0000269|PubMed:17034817, ECO:0000269|PubMed:17442338"
FT   BINDING         222
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250"
FT   BINDING         227
FT                   /ligand="substrate"
FT   BINDING         270..280
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000269|PubMed:11513593,
FT                   ECO:0000269|PubMed:11514561, ECO:0000269|PubMed:15929998,
FT                   ECO:0000269|PubMed:17034817, ECO:0000269|PubMed:17442338"
FT   SITE            84
FT                   /note="Lowers pKa of active site Tyr"
FT                   /evidence="ECO:0000250"
FT   VAR_SEQ         124..139
FT                   /note="PGEEVIPKDENGKILF -> EDIGILTWKKSPKHNS (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_043779"
FT   VAR_SEQ         140..323
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_043780"
FT   VARIANT         46
FT                   /note="F -> Y (in dbSNP:rs2854482)"
FT                   /evidence="ECO:0000269|PubMed:7959017"
FT                   /id="VAR_048216"
FT   VARIANT         79
FT                   /note="I -> V (in SRXY8; partially impaired activity;
FT                   dbSNP:rs387906750)"
FT                   /evidence="ECO:0000269|PubMed:21802064"
FT                   /id="VAR_066632"
FT   VARIANT         90
FT                   /note="H -> Q (in SRXY8; partially impaired activity;
FT                   dbSNP:rs797044460)"
FT                   /evidence="ECO:0000269|PubMed:21802064"
FT                   /id="VAR_066633"
FT   VARIANT         172
FT                   /note="L -> Q (in dbSNP:rs11474)"
FT                   /id="VAR_014748"
FT   VARIANT         222
FT                   /note="H -> Q (in SRXY8; partially impaired activity;
FT                   dbSNP:rs13222)"
FT                   /evidence="ECO:0000269|PubMed:21802064"
FT                   /id="VAR_066634"
FT   VARIANT         300
FT                   /note="N -> T (in SRXY8; partially impaired activity;
FT                   dbSNP:rs387906751)"
FT                   /evidence="ECO:0000269|PubMed:21802064"
FT                   /id="VAR_066635"
FT   MUTAGEN         24
FT                   /note="Y->A: Strongly decreases affinity for
FT                   androstenedione. Decreases androstenedione reductase
FT                   activity about 60-fold."
FT                   /evidence="ECO:0000269|PubMed:17442338"
FT   MUTAGEN         31
FT                   /note="K->A,M: Increases the low androstenedione reductase
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:17442338"
FT   MUTAGEN         301
FT                   /note="R->A: Decreases 3-alpha-hydroxysteroid reductase
FT                   activity about 50-fold."
FT                   /evidence="ECO:0000269|PubMed:15929998"
FT   MUTAGEN         304
FT                   /note="R->A: Decreases 3-alpha-hydroxysteroid reductase
FT                   activity about 500-fold."
FT                   /evidence="ECO:0000269|PubMed:15929998"
FT   CONFLICT        76
FT                   /note="R -> S (in Ref. 12; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        87
FT                   /note="S -> C (in Ref. 12; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        93
FT                   /note="E -> EE (in Ref. 12; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        111
FT                   /note="V -> A (in Ref. 3; AAB38486)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        164
FT                   /note="G -> R (in Ref. 7; BAF82993)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        179
FT                   /note="K -> E (in Ref. 1; AAD14013 and 3; AAB38486)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        185
FT                   /note="K -> E (in Ref. 1; AAD14013 and 3; AAB38486)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        188
FT                   /note="C -> H (in Ref. 12; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        193
FT                   /note="C -> H (in Ref. 12; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        319
FT                   /note="F -> I (in Ref. 1; AAD14013 and 3; AAB38486)"
FT                   /evidence="ECO:0000305"
FT   STRAND          7..9
FT                   /evidence="ECO:0007829|PDB:4XO6"
FT   STRAND          15..22
FT                   /evidence="ECO:0007829|PDB:4XO6"
FT   HELIX           32..44
FT                   /evidence="ECO:0007829|PDB:4XO6"
FT   STRAND          48..50
FT                   /evidence="ECO:0007829|PDB:4XO6"
FT   HELIX           53..55
FT                   /evidence="ECO:0007829|PDB:4XO6"
FT   HELIX           58..70
FT                   /evidence="ECO:0007829|PDB:4XO6"
FT   HELIX           76..78
FT                   /evidence="ECO:0007829|PDB:4XO6"
FT   STRAND          80..85
FT                   /evidence="ECO:0007829|PDB:4XO6"
FT   HELIX           87..89
FT                   /evidence="ECO:0007829|PDB:4XO6"
FT   HELIX           92..106
FT                   /evidence="ECO:0007829|PDB:4XO6"
FT   STRAND          111..116
FT                   /evidence="ECO:0007829|PDB:4XO6"
FT   STRAND          119..122
FT                   /evidence="ECO:0007829|PDB:4JQA"
FT   STRAND          124..126
FT                   /evidence="ECO:0007829|PDB:4JQA"
FT   HELIX           144..156
FT                   /evidence="ECO:0007829|PDB:4XO6"
FT   STRAND          159..167
FT                   /evidence="ECO:0007829|PDB:4XO6"
FT   HELIX           170..177
FT                   /evidence="ECO:0007829|PDB:4XO6"
FT   STRAND          187..192
FT                   /evidence="ECO:0007829|PDB:4XO6"
FT   HELIX           200..208
FT                   /evidence="ECO:0007829|PDB:4XO6"
FT   STRAND          212..217
FT                   /evidence="ECO:0007829|PDB:4XO6"
FT   TURN            225..227
FT                   /evidence="ECO:0007829|PDB:4XO6"
FT   HELIX           235..237
FT                   /evidence="ECO:0007829|PDB:4XO6"
FT   HELIX           239..248
FT                   /evidence="ECO:0007829|PDB:4XO6"
FT   HELIX           252..262
FT                   /evidence="ECO:0007829|PDB:4XO6"
FT   STRAND          266..270
FT                   /evidence="ECO:0007829|PDB:4XO6"
FT   HELIX           274..281
FT                   /evidence="ECO:0007829|PDB:4XO6"
FT   HELIX           282..285
FT                   /evidence="ECO:0007829|PDB:4XO6"
FT   HELIX           290..297
FT                   /evidence="ECO:0007829|PDB:4XO6"
FT   HELIX           309..311
FT                   /evidence="ECO:0007829|PDB:4XO6"
FT   STRAND          319..321
FT                   /evidence="ECO:0007829|PDB:4XO6"
SQ   SEQUENCE   323 AA;  36735 MW;  0D7B6F983FCE85E1 CRC64;
     MDSKYQCVKL NDGHFMPVLG FGTYAPAEVP KSKALEAVKL AIEAGFHHID SAHVYNNEEQ
     VGLAIRSKIA DGSVKREDIF YTSKLWSNSH RPELVRPALE RSLKNLQLDY VDLYLIHFPV
     SVKPGEEVIP KDENGKILFD TVDLCATWEA MEKCKDAGLA KSIGVSNFNH RLLEMILNKP
     GLKYKPVCNQ VECHPYFNQR KLLDFCKSKD IVLVAYSALG SHREEPWVDP NSPVLLEDPV
     LCALAKKHKR TPALIALRYQ LQRGVVVLAK SYNEQRIRQN VQVFEFQLTS EEMKAIDGLN
     RNVRYLTLDI FAGPPNYPFS DEY
//
